TNF and COVID-19: The study revealed that TNF-α blocker prescriptions like adalimumab, infliximab, and etanercept significantly decreased the risk of developing severe COVID-19 in the patients, with adalimumab having the highest preventive rate (96.8%) against severe COVID-19.